GLP-1 Market
LLY $1406.29 ▼ -1.8% NVO $40.70 ▼ -2.2% PFE $28.41 ▼ -1.6% VKTX $26.65 ▼ -0.6% KLRA $12.08 ▼ -3.9% GPCR $18.06 ▼ -2.7% RHHBY $60.95 ▲ +1.1%
Market data delayed up to 20 min · Source: Twelve Data
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

AMT-162

AMT-162

Company
UniQure Biopharma B.V.
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Nov 17, 2026

Trial details
  • Active, not recruiting NCT NCT06100276

    Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)

    Not yet reported, Not yet reported UniQure Biopharma B.V. 20 participants Est. completion 2031-11-30 12 sites Stand-alone
    Other conditions: Amyotrophic Lateral Sclerosis
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.